Biscayne Neurotherapeutics acquired its huperzine A platform as a result of a merger with epilepsy drug developer Insero Health in 2015. The huperzine A program was pioneered by leading epilepsy experts, most notably, the work of neurology professor Dr. Steven Schachter of Harvard Medical School, an internationally known epilepsy researcher and clinician. The merger also brought senior executives with extensive experience in the development and commercialization of novel epilepsy therapeutics to Biscayne.

Lead compound BIS-001 is a highly potent and selective acetylcholinesterase inhibitor (AChE) that is a synthetic form of a traditional Chinese medicine widely used to treat central nervous system ailments. The efficacy of BIS-001 has been demonstrated in multiple CNS disease models, including pain and difficult-to-treat epileptic conditions, such as refractory complex partial seizures and Dravet syndrome. In a Phase Ia study in adults with drug resistant complex partial epilepsy, BIS-001 was safe and serum levels were determined which are predictive of effective drug levels. Biscayne’s technology is licensed from Harvard University, Yale University and the University of South Florida.

Biscayne Neurotherapeutics has an experienced executive team with an extensive track record of successful drug development, and its scientific advisors include a number of highly respected experts studying seizure and other CNS disorders. The company is headquartered in Miami, Florida, and benefits from the growing entrepreneurial South Florida biomedical sector.